Michelle Hoffman

At a time when the industry is struggling with innovation, it might do well to learn a lesson from a few great innovators.

A report commissioned by FDA evaluates the QbD paradigm.

Are biosimilars the next big thing or just the next big bubble?

Which route will we take to arrive at a national stem-cell policy?